Dougherty Ashley C, Hawaz Mariam G, Hoang Kristine G, Trac Judy, Keck Jacob M, Ayes Carmen, Deweese Joseph E
Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy and Health Sciences, One University Park Drive, Nashville, Tennessee 37204-3951, United States.
Department of Biochemistry, Vanderbilt University School of Medicine, 2215 Garland Avenue, Nashville, Tennessee 37232-0146, United States.
ACS Omega. 2021 Sep 30;6(40):25892-25903. doi: 10.1021/acsomega.1c02083. eCollection 2021 Oct 12.
Human topoisomerase IIα (TOP2A) is a vital nuclear enzyme involved in resolving knots and tangles in DNA during replication and cell division. TOP2A is a homodimer with a symmetrical, multidomain structure. While the N-terminal and core regions of the protein are well-studied, the C-terminal domain is poorly understood but is involved in enzyme regulation and is predicted to be intrinsically disordered. In addition, it appears to be a major region of post-translational modification and includes several Ser and Thr residues, many of which have not been studied for biochemical effects. Therefore, we generated a series of human TOP2A mutants where we changed specific Ser and Thr residues in the C-terminal domain to Ala, Gly, or Ile residues. We designed, purified, and examined 11 mutant TOP2A enzymes. The amino acid changes were made between positions 1272 and 1525 with 1-7 residues changed per mutant. Several mutants displayed increased levels of DNA cleavage without displaying any change in plasmid DNA relaxation or DNA binding. For example, mutations in the regions 1272-1279, 1324-1343, 1351-1365, and 1374-1377 produced 2-3 times more DNA cleavage in the presence of etoposide than wild-type TOP2A. Further, several mutants displayed changes in relaxation and/or decatenation activity. Together, these results support previous findings that the C-terminal domain of TOP2A influences catalytic activity and interacts with the substrate DNA. Furthermore, we hypothesize that it may be possible to regulate the enzyme by targeting positions in the C-terminal domain. Because the C-terminal domain differs between the two human TOP2 isoforms, this strategy may provide a means for selectively targeting TOP2A for therapeutic inhibition. Additional studies are warranted to explore these results in more detail.
人类拓扑异构酶IIα(TOP2A)是一种重要的核酶,在DNA复制和细胞分裂过程中参与解开DNA中的结和缠结。TOP2A是一种具有对称多结构域结构的同二聚体。虽然该蛋白的N端和核心区域已得到充分研究,但C端结构域了解较少,不过它参与酶的调节,并且预计是内在无序的。此外,它似乎是翻译后修饰的主要区域,包含几个丝氨酸(Ser)和苏氨酸(Thr)残基,其中许多残基的生化效应尚未得到研究。因此,我们构建了一系列人类TOP2A突变体,将C端结构域中的特定Ser和Thr残基替换为丙氨酸(Ala)、甘氨酸(Gly)或异亮氨酸(Ile)残基。我们设计、纯化并检测了11种突变型TOP2A酶。氨基酸变化发生在1272至1525位之间,每个突变体有1至7个残基发生改变。几个突变体表现出DNA切割水平增加,而质粒DNA松弛或DNA结合没有任何变化。例如,在1272 - 1279、1324 - 1343、1351 - 1365和1374 - 1377区域的突变在依托泊苷存在的情况下产生的DNA切割比野生型TOP2A多2至3倍。此外,几个突变体在松弛和/或解连环活性方面表现出变化。总之,这些结果支持了之前的发现,即TOP2A的C端结构域影响催化活性并与底物DNA相互作用。此外,我们推测有可能通过靶向C端结构域中的位置来调节该酶。由于两种人类TOP2同工型的C端结构域不同,这种策略可能为选择性靶向TOP2A进行治疗性抑制提供一种手段。有必要进行更多研究以更详细地探索这些结果。